CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility

Funding will be used to a advance GEMS Flex And 14-Day Holter/LTCM ECG Platform

Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of $512,000.

The Loan Agreement provides new working capital to complete and commercialize the Company's GEMS FLEX and 14-day Holter and Event long term continuous monitoring ("LTCM") ECG software platform (the "Flagship Product"). The Flagship Product is expected to become CardioComm's principal offering and major source of revenue, providing healthcare professionals and patients with new and advanced remote monitoring and ECG analysis capabilities. This financing transaction will enable the Company to:

• Finalize the Flagship Product for a full market-ready release;
• Conduct structured user feedback reviews to refine usability and performance;
• Launch and market the Flagship Product to targeted healthcare markets; and
• Provide post-launch customer support and installation services.

Pursuant to the Loan Agreement, the Company has issued an aggregate of 345,600 common shares of the Company (each, a "Bonus Share") and 6,912,000 common share purchase warrants of the Company (each, a "Bonus Warrant") to certain of the lenders under the Loan Agreement, as follows: 280,000 Bonus Shares and 5,600,000 Bonus Warrants to Xemxija Holdings Inc. ("Xemxija", a company controlled by Daniel Grima, a director of CardioComm); and 65,600 Bonus Shares and 1,312,000 Bonus Warrants to ITF Ventures Inc. ("ITF", a company controlled by Daniel Grima and Etienne Grima, CEO and a director of CardioComm). Each Bonus Warrant is exercisable to acquire one Company common share at an exercise price of $0.05 until November 3, 2030. The Bonus Shares, the Bonus Warrants, and the shares issuable under the Bonus Warrants are subject to a four month hold period expiring March 11, 2026.